Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Definium Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $721.7K in total
- Insiders trading
- 1
- Net value
- −$721.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Definium Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vallone Carol A | Director | 22,296 | Sep 18, 2026 | 2 |
| Krebs Andreas | Director | 21,402 | Sep 18, 2026 | 2 |
| Karlin Dan | Chief Medical Officer | 803,699 | Sep 14, 2026 | 7 |
| Wiley Matthew T. | Chief Commercial Officer | 362,133 | Sep 14, 2026 | 5 |
| Sullivan Mark | Chief Legal Officer | 508,279 | Sep 14, 2026 | 7 |
| Roberts Brandi | Chief Financial Officer | 397,905 | Sep 14, 2026 | 5 |
| Barrow Robert | Chief Executive Officer | 2,244,640 | Sep 14, 2026 | 8 |
| Gryska David W | Director | 19,900 | Jun 15, 2026 | 1 |
| Bruhn Suzanne Louise | Director | 24,289 | Jun 15, 2026 | 1 |
| Crystal Roger | Director | 24,289 | Jun 15, 2026 | 1 |
| Adsett Roger | Director | 3,555 | Jun 15, 2026 | 2 |
| Liao Carrie | Chief Accounting Officer | 144,923 | Mar 26, 2025 | 0 |
| Wernli Miri Halperin | Executive President | 202,405 | Aug 22, 2024 | 0 |
| Greenway Schond L. | Chief Financial Officer | 211,057 | Mar 26, 2024 | 0 |
| Makes Brigid | Director | 158,706 | Jun 6, 2022 | 0 |
| Hu Cynthia W. | Chief Legal Officer&Secretary | 1,200,000 | Mar 28, 2022 | 0 |
| Hurst Stephen L | Director, Other: Former Director | – | Mar 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Sullivan MarkChief Legal Officer | SSale | −6.58K | $6.74 | −$44.3K | −2.0%316.6K after | 10b5-1 |
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Karlin DanChief Medical Officer | SSale | −6.84K | $6.74 | −$46.1K | −1.5%446.2K after | 10b5-1 |
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Barrow RobertChief Executive Officer | SSale | −21.2K | $6.74 | −$142.9K | −2.4%856.6K after | 10b5-1 |
| Jun 26, 2025 (view filing) | Jun 25 | 1 day | Barrow RobertChief Executive Officer | SSale | −26.5K | $6.80 | −$180.1K | −3.1%830.1K after | 10b5-1 |
| Jun 26, 2025 (view filing) | Jun 25 | 1 day | Karlin DanChief Medical Officer | SSale | −7.85K | $6.80 | −$53.4K | −1.8%438.3K after | 10b5-1 |
| Jun 26, 2025 (view filing) | Jun 25 | 1 day | Sullivan MarkChief Legal Officer | SSale | −11.5K | $6.80 | −$78.1K | −3.6%305.1K after | 10b5-1 |
| Sep 26, 2025 (view filing) | Sep 25 | 1 day | Karlin DanChief Medical Officer | SSale | −7.70K | $9.77 | −$75.3K | −1.8%430.6K after | 10b5-1 |
| Sep 26, 2025 (view filing) | Sep 25 | 1 day | Barrow RobertChief Executive Officer | SSale | −25.8K | $9.77 | −$252.0K | −3.1%804.3K after | 10b5-1 |
| Sep 26, 2025 (view filing) | Sep 25 | 1 day | Sullivan MarkChief Legal Officer | SSale | −11.3K | $9.77 | −$110.2K | −3.7%293.9K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Sullivan MarkChief Legal Officer | SSale | −11.3K | $13.15 | −$148.3K | −3.8%282.6K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Barrow RobertChief Executive Officer | SSale | −25.8K | $13.15 | −$339.2K | −3.2%778.5K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Karlin DanChief Medical Officer | SSale | −5.60K | $13.15 | −$73.6K | −1.3%425.0K after | 10b5-1 |
| Mar 26, 2026 (view filing) | Mar 25 | 1 day | Barrow RobertChief Executive Officer | SSale | −24.4K | $18.47 | −$451.2K | −3.1%752.5K after | 10b5-1 |
| Mar 26, 2026 (view filing) | Mar 25 | 1 day | Sullivan MarkChief Legal Officer | SSale | −10.7K | $18.47 | −$197.7K | −3.8%271.1K after | 10b5-1 |
| Mar 26, 2026 (view filing) | Mar 25 | 1 day | Karlin DanChief Medical Officer | SSale | −8.02K | $18.47 | −$148.1K | −1.9%413.3K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Wiley Matthew T.Chief Commercial Officer | SSale | −2.87K | $45.03 | −$129.1K | −1.6%174.6K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Barrow RobertChief Executive Officer | SSale | −29.2K | $45.03 | −$1.32M | −2.6%1.10M after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Roberts BrandiChief Financial Officer | SSale | −3.01K | $45.03 | −$135.7K | −1.4%209.5K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Karlin DanChief Medical Officer | SSale | −10.0K | $45.03 | −$451.9K | −2.0%503.3K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Sullivan MarkChief Legal Officer | SSale | −13.0K | $45.03 | −$585.8K | −3.9%320.6K after | 10b5-1 |
| Sep 4, 2026 (view filing)9:30 PM ET | Sep 3 | 1 day | Barrow RobertChief Executive Officer | SSale | −19.0K | $37.94 | −$721.7K | −1.3%1.49M after | 10b5-1 |